Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective

Jing Cui; Yanfei Liu; Yiwen Li; Fengqin Xu; Yue Liu

doi:10.3389/fcvm.2021.644189

Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective

Front Cardiovasc Med. 2021 Feb 24:8:644189. doi: 10.3389/fcvm.2021.644189. eCollection 2021.

Authors

Jing Cui^{1

2}, Yanfei Liu³, Yiwen Li^{1

2

4}, Fengqin Xu^{2

4}, Yue Liu^{1

2

4}

Affiliations

¹ Cardiovascular Centre of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
² National Clinical Research Centre for Chinese Medicine Cardiology, Beijing, China.
³ Institute of Clinical Pharmacology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
⁴ China Center for Evidence-Based Medicine of Chinese Medicine, Beijing, China.

Abstract

Type 2 diabetes mellitus (T2DM) and its complications are seriously affecting public health worldwide. Myocardial infarction (MI) is the primary cause of death in patients with T2DM. T2DM patients without a history of coronary artery disease (CAD) have the same risk of major coronary events as those with CAD; T2DM patients with a history of MI have >40% risk of recurrence of MI. Thus, CAD in patients with T2DM needs to be treated actively to reduce the risk of MI. The cardiology community focused on the role of T2DM in the development of CAD and on the related issues of T2DM and MI with respect to comorbidities, prognosis, drug therapy, and heredity. In this mini review, the latest progress of clinical evidence-based research between T2DM and MI in recent years was reviewed, and the possible research directions in this field were considered and prospected.

Keywords: drug; evidence-based medicine; myocardial infarction; sodium-glucose cotransporter-2 inhibitor; type 2 diabetes.

Publication types

Review